Multinational Pharma Giants Deliver Tangible AI Results in Q1 2026 Earnings Season

May 08, 2026 11:06 CST Updated 11:06

AstraZeneca

Pharmaceutical Technology Research and Development Provider

GSK

Pharmaceutical R&D Manufacturer

The Q1 2026 earnings season has officially concluded. Unlike the previous narrative approach where industries generally emphasized AI concepts and painted long-term development blueprints, global leading pharmaceutical giants such as AstraZeneca, GSK, Bristol-Myers Squibb (BMS), Merck, and Novo Nordisk have all unveiled practical applications of AI technology during this earnings release and conference calls.Quantifiable Outcomes，Allowing AI-driven drug discovery to move from "theory on paper" to truly "practical implementation."

From significantly compressing the new drug R&D cycle, to precisely selecting clinical patients, to deeply exploring the potential value of M&A targets, AI has completely shed the label of "concept hype" and is now fully integrated into the entire value chain of the pharmaceutical industry. It has become a key engine driving revenue growth for pharmaceutical companies and building core competitive barriers.

AstraZeneca: End-to-End Full Chain Layout, AI Has Achieved Tangible Value Delivery

As the pharmaceutical company with the most detailed disclosure of AI implementation achievements in this earnings season, AstraZeneca has specially set up an AI-exclusive section in its earnings report to comprehensively showcase the practical results of its AI technology in core areas such as R&D, clinical trials, and production. It explicitly positions AI as a core supporting force to achieve the 2030 revenue target of $80 billion.

At the source stage of new drug discovery, AstraZeneca's self-developed open-source generative AI frameworkReinvent, has successfully halved the identification cycle of potential new drug molecular structures. AstraZeneca CEO Pascal Soriot stated bluntly on the earnings call that this framework "has fundamentally changed the pace of advancing from drug concept to lead molecules, significantly improving the efficiency of new drug discovery."

In the clinical development phase, its self-developed quantitative continuous scoring algorithm platformQCS, which can digitally process images of patient tissue samples to precisely quantify the expression levels of targets on the surface and within tumor cells, thereby identifying patients most likely to benefit from treatment. Currently, this platform has been officially applied in the Phase III clinical trial of the TROP2-targeted ADC drug Datroway to assess the probability of non-small cell lung cancer patients benefiting from the medication, providing scientific support for clinical decision-making.

On the production side, AstraZeneca has developed an AI-powered Agent system with the core objective of halving the development cycle for Chemistry, Manufacturing, and Control (CMC). By integrating simulation technologies, vast industry data, and internal professional expertise, this system is expected to fundamentally transform the development model for synthetic drugs, reducing costs and risks in the production process.

"AI is transforming the way we work, being fully integrated into AstraZeneca's entire business process— from drug discovery and clinical development to commercial operations and healthcare service delivery." Pascal Soriot emphasized, "This is not a vision of the future; it is a reality happening now. AI is already delivering real, measurable value across our entire value chain."

GSK: Anchoring Innovation Core Priorities, Unlocking "Hidden Value" in BD M&A with AI

Unlike AstraZeneca's full-chain layout, GSK has a clear prioritization for AI applications. GSK CEO Luke Miels explicitly stated during the earnings call that the "top priority for AI application is the innovation dimension," focusing on areas that can bring long-term core competitiveness to the company.

Luke Miels further explained that process optimization, cost control, and other conventional scenarios can mostly be achieved through off-the-shelf commercial AI solutions. Meanwhile, the company’s self-developed investments and core AI talent will all focus on the R&D stage, particularly the translational medicine phase at the earliest stage of drug development, as well as innovation at the source of drug molecule design, to build a differentiated competitive advantage.

More noteworthy for the industry is that GSK has deeply integrated AI technology into its mergers and acquisitions (M&A) and business development (BD) strategies. In recent years, GSK has continued to strategically acquire potential competitors of established blockbuster drugs through M&A, with AI serving as a key tool for uncovering the core value of targets and mitigating investment risks.

"The core key lies in our ability to use AI technology to assess the development potential of a drug more comprehensively and accurately, as well as identify potential application scenarios that have not yet been discovered by the industry," said Luke Miels. "This is not only crucial for optimizing our internal pipeline but also central to the value of our BD business — we can use this to identify untapped value in companies or products, find pricing gaps in the market, and achieve precise M&A positioning."

BMS: Efficiency Improvement Throughout the Entire R&D Cycle, Core Target of Reducing Clinical Cycle by 30% Locked

Bristol-Myers Squibb (BMS) has identified the scaled application of AI tools and laboratory automation as the two key areas of investment in core R&D infrastructure, setting clear and quantifiable efficiency improvement goals to drive the deep integration of AI with R&D operations.

BMS CEO Chris Boerner stated on the earnings call that the company's core objective is to halve the cycle time for target selection and molecule design through AI technology. At the same time, by implementing a more rigorous and scientific evaluation system, only the most differentiated and clinically valuable molecules will advance to the later stages of development, thereby increasing the success rate of R&D.

In the later stages of drug development, BMS has widely applied AI to optimize clinical operations, achieving the dual goals of shortening the R&D cycle and upgrading quality supervision. "We estimate that these AI-driven initiatives will reduce the overall R&D cycle by 30% compared to a few years ago," revealed Chris Boerner. In March this year, the company reached an in-depth collaboration with Faro to scale AI-driven workflows across the design, protocol writing, validation, and full-process optimization of clinical trials, further enhancing the efficiency of clinical development.

Group cooperation becomes the mainstream of the industry, giants lock in top AI players

Given the complexity and diversity of AI technology, it is difficult for enterprises to cover all-scenario application needs through independent research and development alone. Establishing in-depth strategic cooperation with leading technology companies has become another major trend for multinational pharmaceutical companies to deploy AI, achieving "complementary advantages and collaborative win-win outcomes."

In April this year, Novo Nordisk followed in the footsteps of Sanofi and Eli Lilly by officially partnering with OpenAI. The core objective is to fully integrate AI capabilities "from drug discovery to commercial operations across global business." Just days before the announcement of the collaboration, OpenAI had released a new reasoning model specifically designed for biology, drug discovery, and translational medical research.GPT-Rosalind, which has been opened to relevant cooperative customers through the Trusted Access Program, providing more precise technical support for pharmaceutical companies.

On the other hand, Merck has chosen to enter into an AI strategic partnership with Google Cloud. This investment, which is worth up to 1 billion US dollars, will allow Merck to fully integrate Google Cloud’s Agentic AI platform across its R&D, manufacturing, commercial teams, and corporate functional departments. Leveraging the technological advantages of Google Cloud, this collaboration aims to accelerate the implementation of AI throughout the entire business chain.

Merck CEO Robert Davis said on the earnings call that, in addition to the deep collaboration with Google Cloud, the company has also partnered with Tempus AI to accelerate the discovery of precision medicine biomarkers. Meanwhile, a collaboration with Mayo Clinic has been established to access high-quality lab test results, medical imaging, clinical records, and molecular data, providing solid data support for the training and validation of AI models in drug discovery.

"These collaborative initiatives have not only significantly improved the operational efficiency of the entire enterprise but have also created real opportunities for innovative breakthroughs in our pipeline – enabling us to bring more high-quality new drugs to patients in need at a faster speed and with a higher success rate," said Robert Davis.

Industry Watershed Arrives: AI Drug Development Enters the "Prove Effectiveness" Era from "Storytelling"

In the past few years, the industry's discussion on AI pharmaceuticals has always been accompanied by the controversy of "whether it can be implemented and whether it can create real value." The AI layout of most pharmaceutical companies has also mostly remained in the stages of long-term planning and concept verification, failing to form substantive value output.

The earnings season of the first quarter of 2026, where the world's top pharmaceutical companies collectively delivered their AI implementation results, has completely heralded the arrival of the era of full-scale AI-driven drug discovery. From early target discovery and molecular design to clinical development, CMC production, and further to commercial operations and BD mergers and acquisitions, AI technology has comprehensively penetrated every core aspect of the pharmaceutical industry, delivering quantifiable, verifiable, and replicable value outcomes, dispelling industry skepticism about AI-driven drug discovery.

It can be foreseen that in the near future, the strength of AI capabilities will directly determine pharmaceutical companies' R&D efficiency, cost control ability, and growth potential. The competitive landscape of the global pharmaceutical industry will also undergo a complete reconstruction and reshuffling driven by this AI-powered industrial revolution.

Reference Source:https://www.fiercebiotech.com/biotech/drug-development-ma-big-pharmas-showcase-measurable-impact-ai

Scan the WeChat QR code to add.Medicine Space-TimeEditor

Please indicate: Name + Research Direction!